Growth trends for Reata Pharmaceuticals

Reata Pharmaceuticals (RETA) is one of the best-performing biotechnology companies, rising 218.71% YTD (year-to-date). It’s involved in the evaluation of several investigational drugs, including first-in-class Nrf2, RORγt, and Hsp90 modulators that target diseases with high unmet demands.

Reata Pharmaceuticals is currently involved in the following three pivotal trials:

  • Phase 2/3 CARDINAL trial evaluating bardoxolone methyl in a rare chronic kidney disease (or CKD) due to Alport syndrome
  • Phase 2 MOXIe trial evaluating Omav in Friedreich’s Ataxia
  • Phase 3 CATALYST trial evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (or CTD-PAH)

Data from the CARDINAL trial is anticipated in the second half of 2019. Data from the MOXIe and CATALYST trials are expected in the second half of 2019 and the first half of 2020, respectively.

In Q2 2018, Reata Pharmaceuticals reported revenues of $7.6 million, which was a YoY (year-over-year) decline of 40.9%. It missed its consensus revenue and EPS estimates by $2.2 million and $1.10, respectively. Wall Street analysts expect Reata Pharmaceuticals to post $59.8 million in revenues in 2018, which is a YoY rise of 24.4%.

Reata Pharmaceuticals: One of Best-Performing Biotech Stocks YTD

Reata Pharmaceuticals is also enrolling patients in PHOENIX, an open-label Phase 2 trial evaluating bardoxolone methyl in four rare CKDs: autosomal dominant polycystic kidney disease (or ADPKD), CKD due to Type 1 diabetes (or T1D CKD), IgA nephropathy, and focal segmental glomerulosclerosis (or FSGS). Together, the five targeted rare forms of CKD have a total US prevalence of ~700,000.

Analyst recommendations for Reata Pharmaceuticals

The overall analyst sentiment for Reata Pharmaceuticals on September 12 seems to have improved from the previous month. Of the seven analysts covering the stock in September, six have recommended a “strong buy,” and one has recommended a “buy.”

Wall Street analysts have projected a 12-month consensus target price for Reata Pharmaceuticals of $114.86, which would be an increase of 27.25% over its closing price on September 13.

In the next part of this series, we’ll look at the growth trends for G1 Therapeutics.

Latest articles

This year, Pfizer (PFE) stock has fallen 0.34% and Bristol-Myers Squibb (BMY) stock has fallen 6.48%. Both companies are focused on strengthening their position in the high-growth oncology and immunology markets. Let's take a closer look at each.

Walt Disney’s (DIS) latest movie, Toy Story 4, has reportedly broken records in the opening weekend with $118 million in sales. However, the opening weekend collection was behind analysts’ expectations of at least $150 million in the first weekend.

24 Jun

Will Home Depot’s Upward Momentum to Continue?

WRITTEN BY Rajiv Nanjapla

As of June 21, Home Depot (HD) was trading at $209.39, which implies a rise of 9.7% since the announcement of its first-quarter earnings on May 21. Also, the company was trading at a premium of 32.4% from its 52-week low of $158.09 and a discount of 2.8% from its 52-week high of $215.43.

On June 21, Aurora Cannabis (ACB) made an announcement that indicated that it will move towards higher margin vape products. In addition, the company also believes concentrates and edibles will command higher margins. In anticipation of this development, the company announced the expansion of its facility to capitalize on growth related to these segments.

Shares of Mondelēz International (MDLZ) are scaling new heights thanks to its stellar gains so far this year. Mondelēz stock is up 38.0% on a YTD (year-to-date) basis, and it closed at $55.25—just a shade lower than its 52-week high of $55.71—on June 21.

24 Jun

How Long Will Facebook's Libra Fuel Bitcoin Rally?

WRITTEN BY Mayur Sontakke, CFA, FRM

Ever since the news about Facebook’s (FB) cryptocurrency project broke, Bitcoin has rallied on the hope that Facebook’s entry in the space will help make cryptocurrencies mainstream. Facebook’s cryptocurrency will be called Libra and will be governed by an association with 28 founding members across industries.